Watanabe, Kenichi
Niikura, Naoki
Kikawa, Yuichiro
Oba, Mari
Kobayashi, Kokoro
Tada, Hiroshi
Ozaki, Shinji
Toh, Uhi
Yamamoto, Yutaka
Tsuneizumi, Michiko
Okuno, Toshitaka
Iwakuma, Nobutaka
Takeshita, Takashi
Iwamoto, Takayuki
Ishiguro, Hiroshi http://orcid.org/0000-0002-9859-5932
Masuda, Norikazu
Saji, Shigehira
Funding for this research was provided by:
AstraZeneca
Article History
Received: 1 November 2022
Accepted: 12 March 2023
First Online: 31 March 2023
Declarations
:
: Kenichi Watanabe received personal fees from Chugai, Eli Lilly, Nippon Kayaku, Kyowa-Kirin, Novartis, Taiho, Eisai, Pfizer and Shionogi, outside the submitted work. Naoki Niikura received research funding to Tokai University from Novartis, Chugai, Daiichi Sankyo, Pfizer, Eisai, Eli Lilly and Mochida, honoraria, consultancy, and speaker fees from AstraZeneca, Novartis, Eisai, Eli Lilly, Chugai, Daiichi Sankyo, and Pfizer, outside the submitted work. Yuichiro Kikawa received consulting fee from Daiichi Sankyo, personal fees from AstraZeneca, Novartis, Taiho, Chugai, Daiichi Sankyo, Eisai and Kyowa-Kirin, outside the submitted work. Mari Oba received payment for educational lecture from AstraZeneca and Pfizer, outside the submitted work. Kokoro Kobayashi received personal fees from Pfizer, Chugai, Novartis, Taiho, Eli Lilly and AstraZeneca, outside the submitted work. Hiroshi Tada received research funding to Tohoku University from Taiho, Kyowa-Kirin and Eisai, personal fees from Chugai, Pfizer, Eli Lilly and Daiichi Sankyo, outside the submitted work. Uhi Toh received personal fees from Chugai, Eisai, Eli Lilly, Pfizer, Daiichi Sankyo and Taiho, outside the submitted work. Yutaka Yamamoto received research funding to Kumamoto University Hospital from Chugai, Kyowa-Kirin, Eisai, Daiichi Sankyo, Nippon-Kayaku, Taiho, Takeda, Eli Lilly, Pfizer and Novartis, honoraria for lectures from AstraZeneca, Chugai, Kyowa-Kirin, Novartis, Eli Lilly, Pfizer, Daiichi Sankyo, Nippon Kayaku, Taiho, Eisai, Takeda, MSD, Sysmex and Exact Science, outside the submitted work. Hiroshi Ishiguro received contract fees to Saitama Medical University International Medical Center from Eisai, speaker fees from Pfizer, outside the submitted work. Norikazu Masuda received research funding to Nagoya University Hospital from Chugai, Eli Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis, Sanofi and Kyowa-Kirin, personal fees from Chugai, Pfizer, AstraZeneca, Eli Lilly and Eisai, Representative of a board of directors of Japan Breast Cancer Research Group (JBCRG) unpaid, Board of Directors of Japanese Breast Cancer Society (JBCS) unpaid, outside the submitted work. Shigehira Saji received Grants from Eisai, Takeda and Eli Lilly, Contracted clinical trials from MSD and AstraZeneca, Grant and Contracted clinical trials from Taiho, Chugai and Daiichi Sankyo to Fukushima Medical University, personal fees from Chugai, Kyowa-Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho, Ono and Nippon Kayaku, personal fees for Participation on a Data Safety Monitoring Board or Advisory Board from Chugai/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa-Kirin and Daiichi Sankyo, Executive board member of JBCRG, JBCS, Japanese Society of Medical Oncology (JSMO) and Breast International Group (BIG), outside the submitted work. The other authors have nothing to declare.
: This study was conducted according to the tenets of the declaration of Helsinki and approved by the institutional review board of Fukushima medical university.
: All patients provided written informed consent prior to participation.
: Our manuscript did not contain any individual person’s data in any form (including any individual details, images or videos.